Tumor feeding artery contraction and metastasis inhibition after transarterial chemoembolization combined with apatinib for hepatocellular carcinoma: A propensity score matching study-Reference-Cited by-同舟云学术

Tumor feeding artery contraction and metastasis inhibition after transarterial chemoembolization combined with apatinib for hepatocellular carcinoma: A propensity score matching study

Published:2022-03-02 Issue:6 Volume:52 Page:546-556
ISSN:1386-6346
Container-title:Hepatology Research
language:en
Short-container-title:Hepatology Research

Author:

Cao Yanyan¹²^ORCID,Kan Xuefeng¹²,Chen Lei¹²,Sun Tao¹²,Ouyang Tao¹²,Zhang Weihua¹,Xiong Fu¹²,Liang Bin¹²^ORCID,Zheng Chuansheng¹²

Affiliation:

1. Department of Radiology Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan China

2. Hubei Province Key Laboratory of Molecular Imaging Wuhan China

Publisher

Wiley

Subject

Infectious Diseases,Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/hepr.13759

Reference27 articles.

1. Texas Has the Highest Hepatocellular Carcinoma Incidence Rates in the USA

2. Efficacy and Safety of apatinib in patients with intermediate/advanced hepatocellular carcinoma

3. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial

4. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma

5. Efficacy and safety of raltitrexed‐based transcatheter arterial chemoembolization for intermediate and advanced hepatocellular carcinoma: A multicenter real‐world study

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prognostic related gene index for predicting survival and immunotherapeutic effect of hepatocellular carcinoma;Medicine;2023-11-03

2. What Is the Most Suitable Agent Combined With Apatinib for Transarterial Chemoembolization Treatment in Advanced Hepatocellular Carcinoma Patients? A Systematic Review and Network Meta-analysis;Frontiers in Oncology;2022-05-25